Posted by Michael Wonder on 29 Oct 2020
CADTH publishes final recommendation for Blincyto
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible stakeholders.
The pERC has conditionally recommended the reimbursement of blinatumomab for the treatment of Philadelphia chromosome-negative, CD19 positive, B-cell precursor acute lymphoblastic leukaemia adult and paediatric patients who are in first or second haematologic complete remission and are minimal residual disease positive, if one condition is met.
No prizes to be awarded for guessing the nature of the condition.
